source
- ArriVent shares tumble as lung cancer trial of furmonertinib misses primary goalArriVent BioPharma reported that its late-stage study of furmonertinib in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer did not achieve its primary endpoint. The trial, w…
- Compliance worries keep AI adoption in drug manufacturing low, survey findsA new survey of more than 400 research and manufacturing professionals shows that over 90% of drugmakers have not committed to expanding AI use in regulated drug production. While AI is widely em…